21st Austria weekly - Andritz Valneva FACC CA Immo 08/09/2022 [pic1]Andritz: International technology group Andritz has acquired J. Parpala Oy a major player in the maintenance and repair of environmental equipment for industrial production power generation plants Finland. The company was founded 2011 operates sites Kokkola Kaskinen. This business transaction further strengthens Andritz’s air pollution control activities Finland making it leading service provider inspections maintenance mechanical upgrades spare parts workshop related to filters scrubbers flue gas ducts fans conveyors other operation between boiler stack. will offer these services various industries such as pulp paper biomass ferrous non-ferrous metals chemical/fertilizer segments.Andritz: performance: 1.10% Valneva: Austrian/French
21st Austria weekly - Valneva Rosenbauer 23/06/2022 [pic1]Valneva: Valneva SE an Austrian/French specialty vaccine company today announced that the Committee for Medicinal Products Human Use CHMP of European Medicines Agency EMA has recommended marketing authorization in Europe Valneva’s
21st Austria weekly - Valneva; AT&S 20/06/2022 [pic1]Valneva: Austrian/French vaccine company Valneva and Pfizer announced that they have entered into an Equity Subscription Agreement updated the terms of their Collaboration License for Lyme disease candidate VLA15. As previously on April 26 2022 plans to initiate Phase 3 study VLA15 in third quarter 2022. part Agreement
21st Austria weekly - Valneva Erste Group 16/06/2022 [pic1]Valneva: an Austrian/French specialty vaccine company today announced that it has entered into a settlement agreement with the Government of United Kingdom “HMG” in relation to termination supply for Valneva’s COVID-19 candidate VLA2001. The Company on September 13 2021 had received notice from HMG and termination which Valneva accepted basis HMG’s
21st Austria weekly - Valneva EVN 26/05/2022 [pic1]Valneva: an Austrian/French specialty vaccine company today announced the successful completion of lot-to-lot Phase 3 trial its single-shot chikungunya candidate VLA1553. The final analysis included six-month follow-up data and confirmed topline results reported in December 2021. VLA1553-302 met primary endpoint demonstrating that three consecutively manufactured lots elicited equivalent immune responses measured by neutralizing antibody titer GMT ratios on Day 29 after vaccination.Valneva: performance: -3.91%EVN: Revenue recorded Austrian utility company Group